Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Once-weekly treatment with EX-LAR (considering the potential beneficial effects of GLP-1R activation on cells and weight loss associated with many patients) is a promising potential strategy for diabetes prevention
Al-Alys team emphasized that the modest benefits observed for many outcomes do not diminish the value of these drugs
(By comparison, Novo Nordisks best-seller Wegovy/Ozempic brings in similar multi-billion revenues, but Lillys CAGR in recent quarters has been higher.) Analysts attribute Lillys success to tirzepatides superior weight loss in trials and aggressive marketing
Retatrutides Phase 3 trials will complete over the next 12 to 18 months, providing the data needed for regulatory submissions
US$ 21.96
US$ 29.08
US$ 26.42
US$ 20.27
US$ 27.54
US$ 28.62
US$ 26.17
US$ 22.00
US$ 21.84
US$ 22.97
US$ 28.58
US$ 27.46
